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Edited by Vladimir SkulachevAbstract In this study, we examined the role of aldose
reductase (AR) in regulating the cytotoxic eﬀects of TNF-a on
human umbilical vein endothelial cells. Inhibition of AR by
sorbinil or tolrestat prevented TNF-a-induced increase in Bax
and Bak and the downregulation of Bcl-2. Inhibition of AR
abrogated AP-1 DNA binding activity and prevented the
activation of caspase-3, JNK, and p38 MAPK in cells stimulated
by TNF-a. Exposure to TNF-a also induced apoptotic cell death,
which was attenuated by AR inhibition or antisense ablation.
These observations suggest that AR is a critical regulator of
TNF-a-induced apoptotic signaling in endothelial cells.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Endothelial cell1. Introduction
Cytokines such as TNF-a are expressed locally in the vessel
wall induced growth arrest and apoptosis in endothelial cells
[1,2]. Cytokine-induced endothelial dysfunction and apoptosis
is of signiﬁcance to the development of several pathophysio-
logical disorders. Disseminated endothelial apoptosis contrib-
utes to endotoxin shock [3], acute allograft rejection [4], and
negative ventricular remodeling during heart failure [5].
Moreover, focal loss of endothelium contributes to the erosion
and rupture of advanced atherosclerotic plaques [6].
Signaling events leading to endothelial apoptosis are redox-
sensitive. Apoptotic agents such as TNF-a increase the gen-
eration of reactive oxygen species (ROS) and the outcome of
apoptotic signaling is critically modulated by the cellular redox
state and glutathione levels [7,8]. However, the mechanisms by
which changes in redox state contribute to apoptotic signaling
remain poorly characterized. We have recently reported that
aldose reductase (AR), a member of the aldo-keto reductase
(AKR) superfamily, regulates TNF-a-induced NF-jB activa-
tion in smooth muscle cells [9], and that inhibition of the en-
zyme prevents smooth muscle cell growth in culture [10],
neointimal hyperplasia in balloon-injured arteries [9] and the* Corresponding author. Fax: +1-409-772-9679.
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Structure-activity studies indicate that AR is an eﬃcient
catalyst for removing the aldehyde products of lipid peroxi-
dation [12,13] and that inhibition of the enzyme increases the
accumulation of lipid peroxidation products such as 4-hy-
droxy-trans-2-nonenal (HNE) in hearts subjected to ischemia-
reperfusion [11] or in the kidneys of animals subjected to
chronic systemic inﬂammation [14]. In addition, we have also
observed that inhibition of AR could prevent TNF-a-induced
apoptosis in lens epithelial cells [15]. Other investigators have
also suggested that AR is involved in regulating apoptosis [16].
However, the mechanisms by which inhibition of AR prevents
apoptosis remain unclear. In the present study, we examined
TNF-a-induced growth arrest and cell death in endothelial
cells. Our results show that inhibition of AR prevents apop-
tosis by interrupting several diﬀerent pathways of TNF-a sig-
naling and suggest that AR is essential to the progression of
the apoptotic program triggered by TNF-a.2. Materials and methods
2.1. Reagents and cell culture
Antibodies against Bcl-2, Bak, Bax, Bcl-xl, phospho-JNK and JNK
and phospho-p38 and p38 were obtained from Cell Signaling Inc.
Consensus oligonucleotides for AP-1 transcription factor were ob-
tained from Promega Corp. All other reagents used were of analytical
grade and obtained from Sigma Chem. Co. Recombinant TNF-a was
purchased from Research Diagnostics. Human umbilical vascular en-
dothelial cells (HUVECs) were obtained from ATCC and were
maintained and grown conﬂuent in Ham’s F12K medium supple-
mented with 2 M L-glutamate, 0.1 mg/ml heparin, and 0.05 mg/ml
endothelial growth supplement (ECGS) and 10% FBS at 37 C in a
humidiﬁed atmosphere of 5% CO2. The cells <12 passages were used
for this study.2.2. Measurement of cell viability and apoptosis
The cells were grown to conﬂuency in Ham’s F12K medium and
harvested by trypsinization and were plated 5000 cells/well in a 96-well
plate. Sub-conﬂuent cells were growth-arrested in 0.1% FBS contain-
ing ECGS. After 24 h, TNF-a (2 nM) without or with AR inhibitors
sorbinil or tolrestat were added to the media and the cells were incu-
bated for another 24 h. Cells incubated with the AR inhibitors alone
served as control. Cell viability was determined by cell counts, MTT-
assay and thymidine incorporation as described earlier [9,15] and ap-
optotic cell death was quantiﬁed using ‘‘Cell Death Detection ELISA’’
Kit (Roche Inc.) according to the manufacturer’s instructions. Cas-
pase-3 activity was measured by using the caspse-3-speciﬁc substrate Z-
DEVD-AFC, (CBZ–Asp–Glu–Val–Asp–AFC). The cells with frag-
mented and/or condensed nuclei were classiﬁed as apoptotic cells and
were identiﬁed by using Hoechst 33342 dye.ation of European Biochemical Societies.
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The cytosolic and nuclear extracts were prepared as described [9,15].
Brieﬂy, after indicated treatments, HUVECs were washed with cold
PBS, suspended in 0.4 ml of hypotonic lysis buﬀer (10 mMHEPES, pH
8.0, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5
mM PMSF, 2.0 lg/ml leupeptin, 2.0 lg/ml aprotinin, and 0.5 mg/ml
benzamidine) and incubated on ice for 30 min. After incubation, 12.5
ll of 10% Nonidet P-40 was added and the tubes were vigorously
vortexed for 10 s. The nuclei were pelleted by centrifugation for 30 s at
4000 rpm. The supernatant was collected and recentrifuged at 12 000
rpm for 2 min at 4 C and used as the cytosolic extract. The nuclear
pellet was suspended in 50 ll of cold nuclear extract buﬀer (20 mM
HEPES, pH 8.0, 0.5 M KCl, 1 mM EDTA, 1 mM EGTA, 1 mMDTT,
1 mM PMSF, 2.0 lg/ml leupeptin, 2.0 lg/ml aprotinin, 0.5 mg/mlFig. 1. Inhibition of AR prevents TNF-a cytotoxicity. (A) Serum-starved HU
lM sorbinil or with 2 nM TNF-a in the presence of 0–20 lM sorbinil. Cell g
HUVECs that were either left untreated or treated with 10 lM sorbinil or tol
were either left untreated (control; C) or treated with AR antisense (A), scram
with 2 nM TNF-a for 24 h. The inset shows Western blots of protein extracts
(C) was determined by trypan blue exclusion. Bars represent means S.E.M.
scrambled oligonucleotides (S).benzamidine, and 20% glycerol). Protein concentration in the extracts
was determined using a Protein Assay Kit from Bio-Rad. Consensus
oligonucleotides for AP-1 transcription factors were 50-end labeled
using T4 polynucleotide kinase. The EMSA were performed as de-
scribed earlier [9].
2.4. Western blot analysis
To examine caspase-3 activation, JNK and p38 phosphorylation,
Bcl-2, Bak, Bax and Bcl-xl upregulation, Western blot analyses were
carried out as described earlier [9] using antibodies against PARP,
JNK and phospho-JNK, p38 and phospho-p38, Bcl-2, Bak, Bax and
Bcl-xl. The proteins were transferred to nitrocellulose ﬁlters, probed
with the indicated antibodies and the antigen–antibody complex was
detected by enhanced chemiluminescence (Amersham PharmaciaVECs were stimulated for 24 h with 0–10 nM TNF-a without or with 10
rowth was determined by [3H]thymidine incorporation. (B) Viability of
restat alone or in the presence of 2 nM TNF-a. (C) Serum-starved cells
bled (S) oligonucleotides, or lipofectamine (L) alone and then cultured
of cells using anti-AR antibodies. The number of viable cells in (B) and
(n ¼ 4), **, P < 0:001 versus untreated cells (C) or cells transfected with
K.V. Ramana et al. / FEBS Letters 570 (2004) 189–194 191Biotech, NJ). Immunopositive bands were quantiﬁed by Kodak Alpha
Imager 2000 Scanning Densitometer equipped with the AlphaEaseTM
Version 3.3b software and the average change in fold-intensity was
calculated.
2.5. Statistical analysis
Data are presented as means S.E.M. and P values were determined
by unpaired Student’s t-test.3. Results
To delineate the role of AR in TNF-a-induced HUVECs
apoptosis, we determined the eﬀect of the AR inhibitor –
sorbinil. As shown in Fig. 1A, treatment of serum-starved
HUVECs with TNF-a (1–10 nM) for 24 h decreased
[3H]thymidine incorporation in a concentration-dependent
manner. The decrease in [3H]thymidine incorporation by in-
creasing concentration of TNF-a was attenuated by sorbinil.
In the absence of TNF-a, 1–20 lM sorbinil did not aﬀect
[3H]thymidine incorporation, indicating that inhibition of AR
by itself does not aﬀect DNA synthesis under these conditions.
However, inhibition of thymidine incorporation by TNF-aFig. 2. Inhibition of AR prevents HUVECs apoptosis. Serum-starved cells w
stimulated with 2 nM TNF-a for 24 h. Apoptosis was determined by using th
P < 0:01 versus TNF-a-treated cells, and (B) Hoechst 33342 nuclear dye. Afte
30 min at 4 C. Apoptotic cells with fragmented nuclei and with buds are indic
TNF-a (2 nM) without or with (10 lM) tolrestat.was prevented by sorbinil in a concentration-dependent fash-
ion. At 10 lM sorbinil, the extent of thymidine incorporation
in TNF-a-treated cells was >80% of the untreated cells. From
these data, we conclude that sorbinil abrogates TNF-a-in-
duced inhibition of DNA synthesis.
Inhibition of AR also prevented TNF-a-induced growth
arrest. As shown in Fig. 1B, treatment with TNF-a decreased
cell density, which was prevented upon pretreatment with AR
inhibitors, sorbinil and tolrestat. In the absence of TNF-a,
these inhibitors did not aﬀect cell growth. Because sorbinil and
tolrestat are structurally unrelated compounds, the observa-
tion that inhibition of TNF-a-induced growth arrest is pre-
vented by either of these drugs provides strong evidence
supporting a role of AR in mediating the eﬀects of TNF-a on
cell growth. Nonetheless, the possibility that these drugs have
non-speciﬁc eﬀects is not rigorously excluded. Therefore, we
tested whether inhibition of AR by antisense oligonucleotides
will have similar eﬀects. Transient transfection of HUVECs
with AR antisense decreased the abundance of AR protein by
90% as compared with scrambled oligonucleotide-transfected
cells (Fig. 1C, inset). When cultured with TNF-a for 24 h,
<50% of the cells treated with lipofectamine or scrambledere pre-cultured without or with 10 lM sorbinil or tolrestat and then
e (A) Cell Death ELISA Kit. Bars represent means S.E.M. (n ¼ 4), *,
r treatment, the cells were incubated with 5 lg/ml of Hoechst 33342 for
ated by arrowheads. Cells either left untreated (control) or treated with
Fig. 3. Inhibition of AR prevents TNF-a-induced caspase-3 activation. Serum-starved cells were cultured without or with 10 lM sorbinil or tolrestat
and then stimulated with 2 nM TNF-a for 24 h. (A) Caspase-3 activity and (B) Western blot analysis using anti-PARP antibodies. Bars represent
meansS.E.M. (n ¼ 4), *, P < 0:01 versus TNF-a-treated cells. Panel B shows a representative Western blot prepared from extracts of cells that
were either left untreated (lane 1), or treated with sorbinil (2), tolrestat (3) TNF-a (4), TNF-a+ sorbinil (5), and TNF-a+ tolrestat (6) using anti-
PAPR antibodies.
Fig. 4. Inhibition of AR regulates the expression of Bcl-2 family of
proteins. Serum-starved HUVECs were either left untreated or pre-
incubated with sorbinil or tolrestat (10 lM) for 24 h and were then
stimulated with TNF-a (2 nM) for 24 h. Western blot analysis was
performed from pooled samples of three independent experiments and
were developed using antibodies against Bcl-2 (A), Bcl-xl (B), Bax (C)
and Bak (D) proteins. (E) Data represent meansS.E.M. of three
independent analyses. P < 0:001 versus TNF-a treated cells without
inhibitors.
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trols without TNF-a. Ablation of AR by antisense signiﬁ-
cantly prevented the TNF-a-induced cell death (Fig. 1C).
Because similar results were obtained with AR-antisense and
inhibitors, AR inhibitors were used for most of the subsequent
experiments.
To determine the eﬀects of AR inhibition of apoptosis, we
measured the free histones released upon nucleosomal degra-
dation during apoptosis and Hoechst 33342 staining. As
shown in Fig. 2A, stimulation with TNF-a caused the degra-
dation of nucleosomal histones. Pretreatment of HUVECs
with either sorbinil or tolrestat inhibited TNF-a-induced ap-
optosis by 40%. Additionally, cells treated with TNF-a dis-
played nuclear fragmentation and condensation. However,
treatment with tolrestat prevented these changes (Fig. 2B).
To examine the eﬀects of AR inhibition on known mediators
of apoptosis, we measured TNF-a-induced caspase-3 activa-
tion in HUVECs by caspase-3-speciﬁc substrates as well as
PAPR cleavage. As shown in Fig. 3, stimulation of HUVECs
with TNF-a caused activation of caspase-3 and PARP cleav-
age. However, both sorbinil and tolrestat prevented the TNF-
a-induced caspase-3 activation as well as PARP cleavage.
Next, we determined the eﬀect of AR inhibition on the ex-
pression of Bcl-2 family proteins. Stimulation with TNF-a
down regulated the expression of Bcl-2 (Fig. 4A) and upreg-
ulated the expression of Bax and Bak (Fig. 4C and D). Stim-
ulation with TNF-a did not aﬀect Bcl-xl levels (Fig. 4B).
Tolrestat completely prevented the downregulation of Bcl-2
and upregulation of Bak and Bax by TNF-a, but it did not
aﬀect basal levels of these proteins in the absence of TNF-a
(Fig. 4F).
To determine how inhibition of AR prevents TNF-a sig-
naling, we tested the eﬀects of AR inhibition on JNK and p38
MAPK activation. Stimulation with TNF-a led to a marked
increase in the phosphorylated forms of JNK and p38 MAPK
(Fig. 5A and C), which was prevented in cells treated with
sorbinil. However, total JNK and p38 MAPK were not af-
fected by TNF-a (Fig. 5B and D). In addition to inhibiting
TNF-a-induced activation of JNK and p38 MAPK, treatment
Fig. 5. Inhibition of AR prevents phosphorylation of JNK and p38 activation of AP-1. Serum-starved HUVECs were either left untreated or pre-
incubated with tolrestat (10 lM) for 24 h and then stimulated with TNF-a (0.1 nM). Western blot analysis was performed from pooled samples of
three independent experiments and developed using anti-phosphop38 (A), p38 (B), phosphoJNK (C) and JNK (D) antibodies. (E) Serum-starved
HUVECs were pre-incubated without or with sorbinil and tolrestat (10 lM) for 24 h, and were then stimulated with 0.1 nM TNF-a for 1 h.
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transcription factor AP-1 (Fig. 5E), suggesting that the inhi-
bition of AR abolishes the cytotoxic eﬀects of TNF-a.4. Discussion
The present study shows that inhibition of AR prevents
TNF-a-mediated growth arrest and apoptosis in vascular
endothelial cells. Decreased cytotoxicity of TNF-a appears to
be due to attenuation of apoptotic signaling, inhibition of
stress-activated kinases (JNK and p38), and diminished
stimulation of caspase-3. Inhibition of AR also prevented the
TNF-a-induced decrease in the abundance of Bcl-2 and the
upregulation of Bax and Bak, indicating that inhibition of
AR profoundly aﬀects the apoptotic signaling program of
TNF-a.
Binding of TNF-a to its receptor triggers multiple signaling
events that initiate both cell death and cell survival pathways
[17,18]. Post-receptor events diverge into distinct signaling
pathways leading to the activation of JNK-AP-1 and NF-jB
and the induction of cell death. The outcome of this signaling
is determined by several regulatory mechanisms including
generation of ceramide from sphingomyelin and changes in
the cellular redox state [17,18]. We have shown earlier that
inhibition of AR blocks NF-jB activation and prevents
proliferation of vascular smooth muscle cells [9]. Our current
observations that inhibition of AR prevents TNF-a-induced
JNK and AP-1 activation and apoptotic cell death in endo-thelial cells suggest that in addition to cell survival signaling
(NF-jB and p38 activation), AR is essential also for other
consequences of TNF-a stimulation that result in JNK acti-
vation and apoptosis. Collectively, these results provide
comprehensive support to the notion that AR-sensitive events
are upstream to the dichotomy between JNK and NF-jB
activation and that AR-catalysis is essential for the manifes-
tation of the pleiotrophic eﬀects of TNF-a, including TNF-
a-induced cell death. We propose that inhibition of AR
prevents signaling events common to both JNK activation
and cell death, even though the cell survival signaling, e.g.,
activation of p38 is prevented. The net eﬀect is inhibition of
apoptosis, presumably because the cell death pathways are
more strongly suppressed than the signaling events leading to
cell survival.
The mechanisms by which inhibition of AR promotes cell
survival remain unclear, but may relate to AR-induced
changes in the cellular redox state. Previous studies have
shown that the activation of caspase-3 by TNF-a in endo-
thelial cell is in part due to increased generation of ROS in
the mitochondria [7]. Similarly, ROS could be mediators of
TNF-a signaling leading to the stimulation of Bax and Bak
and the downregulation of Bcl-2. The critical role of redox
changes in TNF-a signaling is suggested by data showing that
treatment with antioxidants simultaneously blocks TNF-a-
induced NF-jB, AP-1, and stress kinase activation [19], as
well as the downregulation of Bcl-2 and apoptosis in HU-
VECs [20]. Thus, inhibition of AR may be concurrently pre-
venting multiple pathways of TNF-a signaling by minimizing
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consumes NADPH has been thought to improve the intra-
cellular reducing environment [20,21]. The NADPH-sparing
eﬀect of AR inhibition could prevent oxidative stress by
supporting reductive catalysis mediated by oxidoreductases
such as glutathione reductase. Nevertheless, a direct antioxi-
dant eﬀect of AR inhibition during TNF-a signaling seems
unlikely because pre-incubation with AR inhibitors was re-
quired to extinguish TNF-a-signaling. This observation sug-
gests that pre-inhibition of AR establishes a metabolic state
that is not conducive to TNF-a signaling and that AR plays a
permissive rather than a mediatory role in TNF-a signaling.
Clearly, extensive future investigations will be required to
elucidate how cellular responses to AR inhibition prevent
cytokine signaling.
The demonstration that inhibition of AR prevents the acti-
vation of stress kinases and apoptotic signaling provides new
avenues for understanding and managing vascular inﬂamma-
tion. Because of its well-studied role in the development of
secondary diabetic complications, several AR inhibitors have
been developed to treat and prevent long-term diabetic com-
plications such as retinopathy, neuropathy, and renal failure
[21,22]. The observation that inhibition of AR prevents en-
dothelial apoptosis suggests that AR inhibitors could be useful
in preventing endothelial injury and dysfunction associated
with several pathophysiological conditions, including sepsis
and atherogenesis.Acknowledgements: This work was supported in part by NIH grants
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